Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
2024年7月8日 - 8:00PM
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic
medicine company, today announced the appointment of Tim Van
Hauwermeiren, co-founder and Chief Executive Officer of argenx SE,
as an independent, non-executive director to its Board of
Directors. Mr. Van Hauwermeiren is a seasoned biotech executive
with over two decades of experience in both general management and
business development across the life sciences and consumer goods
industries.
“Tim is a highly accomplished life-sciences entrepreneur who has
built one of Europe’s most successful biotech companies, and I am
thrilled to welcome him to our Board of Directors,” said R. Nolan
Townsend, Chief Executive Officer of Lexeo Therapeutics. “Tim’s
deep and relevant experience in company building from clinical to
commercial stage will be an invaluable asset to Lexeo as we embark
on our next phase of growth and progress our pipeline into later
stages of clinical and commercial development.”
Mr. Van Hauwermeiren is co-founder, CEO and a Board Member of
argenx, a global immunology company valued at almost $25 billion
focused on severe autoimmune diseases. During his 15-year tenure,
he has overseen the development and launch of the company’s first
commercial product, efgartigimod, for the treatment of multiple
severe autoimmune diseases, and he has expanded the company’s
footprint across Europe, the U.S. and Asia. Additionally during his
time at argenx, Mr. Van Hauwermeiren has secured more than $4
billion in funding through equity raises and business development
transactions with major pharmaceutical companies. Prior to argenx,
Mr. Van Hauwermeiren held roles with increasing levels of
responsibility at Ablynx and Procter & Gamble.
“I am honored to join Lexeo’s Board at this important stage in
the company’s growth,” said Mr. Van Hauwermeiren. “I am impressed
by the company’s innovative science, pipeline and bold thinking,
and I look forward to sharing my experiences and learnings with the
management team as we work to bring life-changing therapies to
patients with devastating genetic diseases.”
Mr. Van Hauwermeiren also serves on the Board of Directors of
iTeos Pharmaceuticals, and previously served on the Board of
Directors of RayzeBio prior to the company’s acquisition by Bristol
Myers Squibb. He holds a B.Sc. and M.Sc. in bioengineering from
Ghent University and an Executive MBA from The Vlerick School of
Management.
About Lexeo Therapeutics Lexeo
Therapeutics is a New York City-based, clinical stage genetic
medicine company dedicated to transforming healthcare by applying
pioneering science to fundamentally change how genetically defined
cardiovascular diseases and APOE4-associated Alzheimer’s disease
are treated. Using a stepwise development approach, Lexeo is
leveraging early proof-of-concept functional and biomarker data to
advance a pipeline of cardiovascular and APOE4-associated
Alzheimer’s disease programs.
Media Response:Janine Bogris (201) 245-6838
janine.bogris@inizioevoke.com
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 6 2024 まで 7 2024
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 7 2023 まで 7 2024